Compare Cassava Sciences Inc (FLNA) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs TotalEnergies SE — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while TotalEnergies SE trades at $79.54 (market cap $178.73B). The key difference: TotalEnergies SE is far larger — about 3363.4× Cassava Sciences Inc's market cap, and TotalEnergies SE pays a 5.25% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | TTE | |
|---|---|---|
Market Cap | $53.14M | $178.73B |
Sector | Health | Energy |
52-Week High | $4.64 | $93.60 |
52-Week Low | $1.09 | $57.39 |
Enterprise Value | -$33.43M | $212.87B |
Dividend Yield | — | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
TotalEnergies (TTE) trades at $80.91, down 0.37% on the day, with strong technical momentum indicated by a bullish moving average signal. The company maintains solid fundamentals with a P/E of 11.92 and ROE of 12.55%, though revenue has declined from $263.3B in 2022 to $182.3B in 2025. Recent news highlights strategic divestments and new energy project developments, while analyst consensus remains strongly positive with 19 buy ratings.
TTE presents a compelling value opportunity with attractive valuation metrics and consistent dividend payments. However, investors face risks from declining revenue trends, geopolitical exposure in oil-producing regions, and regulatory pressures on emissions. The stock's current technical strength and positive analyst sentiment suggest potential upside, but requires monitoring of operational execution and energy market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
